Amplia Therapeutics is raising $12.4 million to fund human clinical trials and drug manufacturing for its drug candidate designed to slow cancer progression.
Therapeutics company primed for growth switzer.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from switzer.com.au Daily Mail and Mail on Sunday newspapers.
FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus on pancreatic and ovarian cancer.